Pipeline gap looms for Immunex

Immunex Corp.'s two recent clinical setbacks could leave it with a weak middle in its product pipeline. The company discontinued a Phase II/III trial of its Enbrel etanercept in patients with chronic heart failure

Read the full 341 word article

How to gain access

Continue reading with a
two-week free trial.